Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Axim Biotechnologies Inc
Bioprojet SCR
Hisamitsu Pharmaceutical Co Inc
Luye Pharma Group Ltd
NLS Pharma Group
Omeros Corp
Relmada Therapeutics Inc
Seelos Therapeutics, Inc.
Seri Therapeutics Inc
Vifor Pharma Ltd
Restless Legs Syndrome - Drug Profiles
(canbidiol + drobinol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-03009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REL-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropinirole hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News & Press Releases
Jan 04, 2021: Luye Pharma Group: LY03009 commenced phase I clinical trial in Australia
Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
Mar 25, 2013: US Patent and Trademark Office awards Seri Therapeutics key patent covering its lead clinical candidate for Parkinson’s disease and restless leg syndrome
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Restless Legs Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Restless Legs Syndrome, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, 2021
Restless Legs Syndrome - Pipeline by Bioprojet SCR, 2021
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2021
Restless Legs Syndrome - Pipeline by Luye Pharma Group Ltd, 2021
Restless Legs Syndrome - Pipeline by NLS Pharma Group, 2021
Restless Legs Syndrome - Pipeline by Omeros Corp, 2021
Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, 2021
Restless Legs Syndrome - Pipeline by Seelos Therapeutics, Inc., 2021
Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, 2021
Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, 2021
Restless Legs Syndrome - Dormant Projects, 2021
Restless Legs Syndrome - Discontinued Products, 2021